Suppr超能文献

罕见非酵母及其他酵母的抗真菌耐药性与现有及正在研发的药物:文献综述

Antifungal Resistance among Less Prevalent Non- and Other Yeasts versus Established and under Development Agents: A Literature Review.

作者信息

Espinel-Ingroff Ana, Cantón Emilia, Pemán Javier

机构信息

VCU Medical Center, Department of Medicine, Richmond, VA 23298, USA.

Severe Infection Research Group, Health Research Institute Hospital La Fe, 46026 Valencia, Spain.

出版信息

J Fungi (Basel). 2021 Jan 4;7(1):24. doi: 10.3390/jof7010024.

Abstract

Fungal diseases and antifungal resistance continue to increase, including those caused by rare or emerging species. However, the majority of the published in vitro susceptibility data are for the most common fungal species. We reviewed the literature in order to pool reference minimal inhibitory concentration (MIC) data (Clinical and Laboratory Standards Institute-CLSI and European Committee on Antimicrobial Susceptibility-EUCAST) for rare/non-prevalent and other yeast species. MIC results were compared with those for , , and . Data were listed for twenty rare and emerging spp., including , as well as two spp., two spp., and five spp. The best detectors of antimicrobial resistance are the breakpoints, which are not available for the less common species. However, epidemiological cutoff values (ECVs/ECOFFs) have been calculated using merely in vitro data for both reference methods for various non-prevalent yeasts and recently the CLSI has established ECVs for other species. The ECV could identify the non-wild type (NWT or mutants) isolates with known resistance mechanisms. Utilizing these ECVs, we were able to report additional percentages of NWT, especially for non-prevalent species, by analyzing the MIC distributions in the literature. In addition, since several antifungal drugs are under development, we are listing MIC data for some of these agents.

摘要

真菌疾病和抗真菌耐药性持续增加,包括由罕见或新出现的菌种引起的疾病。然而,大多数已发表的体外药敏数据是针对最常见的真菌菌种。我们回顾了文献,以便汇总罕见/非流行酵母菌种以及其他酵母菌种的参考最小抑菌浓度(MIC)数据(临床和实验室标准协会 - CLSI以及欧洲抗菌药物敏感性委员会 - EUCAST)。将MIC结果与针对 、 和 的结果进行比较。列出了20种罕见和新出现的 菌种的数据,包括 ,以及两种 菌种、两种 菌种、 和五种 菌种的数据。抗菌药物耐药性的最佳检测指标是断点,但对于不太常见的 菌种尚无可用的断点。然而,已经仅使用体外数据为各种非流行酵母的两种参考方法计算了流行病学临界值(ECV/ECOFF),并且最近CLSI已经为其他 菌种建立了ECV。ECV可以识别具有已知耐药机制的非野生型(NWT或突变体)分离株。通过利用这些ECV,我们能够通过分析文献中的MIC分布报告额外的NWT百分比,特别是对于非流行菌种。此外,由于几种抗真菌药物正在研发中,我们列出了其中一些药物的MIC数据。

相似文献

引用本文的文献

3
Candida albicans and Antifungal Peptides.白色念珠菌与抗真菌肽
Infect Dis Ther. 2023 Dec;12(12):2631-2648. doi: 10.1007/s40121-023-00889-9. Epub 2023 Nov 8.
5
Liposomal amphotericin B-the future.脂质体两性霉素 B——未来。
J Antimicrob Chemother. 2022 Nov 25;77(Suppl_2):ii21-ii34. doi: 10.1093/jac/dkac353.

本文引用的文献

4
Hope on the Horizon: Novel Fungal Treatments in Development.曙光在前:正在研发的新型真菌治疗方法
Open Forum Infect Dis. 2020 Jan 12;7(2):ofaa016. doi: 10.1093/ofid/ofaa016. eCollection 2020 Feb.
5
Drug resistance and tolerance in fungi.真菌的耐药性和耐受性。
Nat Rev Microbiol. 2020 Jun;18(6):319-331. doi: 10.1038/s41579-019-0322-2. Epub 2020 Feb 11.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验